Home > Healthcare > Pharmaceuticals > Finished Drug Form > Hypopigmentation Disorder Treatment Market

Hypopigmentation Disorder Treatment Market Trends

Report ID: GMI8575
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Hypopigmentation Disorder Treatment Market Trends

The growing involvement of the companies in the research and development activities for the development of drugs along with growing clinical trials in the field of dermatology is projected to propel the market over the forecast period. For instance, as per the National Clinical Trials Registry, 41 active trials related to vitiligo were ongoing in the U.S. as of November 23, 2022.
Similarly, in August 2021, clinical trial for the treatment of vitiligo was carried out in Mexico medical facility. Thus, growing clinical trials especially for vitiligo will further support the market expansion.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Hypopigmentation disorder treatment market size was USD 3.1 billion in 2023 and is expected to register 6.1% CAGR from 2024-2032 owing to the increasing prevalence of pigmentation disorders such as vitiligo and albinism, along with rising awareness among the population worldwide.

The albinism segment and is expected to register 5.9% CAGR from 2024-2032 due to pharmaceutical companies and research institutions actively engaging in developing novel therapeutics targeting melanin production.

North America hypopigmentation disorder treatment industry held 43.2% share in 2023 and is expected to register a commendable CAGR from 2024-2032 due to advanced healthcare infrastructure, high healthcare expenditure, and increase in the skin procedures in the region.

AbbVie Inc., Aclaris Therapeutics, Inc., Bayer AG, Candela Corporation, Galderma, Incyte, Novartis AG, Pfizer Inc., Pierre Fabre group, Shiseido Company Limited, and UNIZA Group, are some of the major hypopigmentation disorder treatment companies worldwide.